STOCK TITAN

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)

UroGen Pharma announced promising results from the Phase 3 ENVISION study of UGN-102 for treating low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC). The study showed an 82.3% duration of response at 12 months in patients achieving complete response. The trial met its primary endpoint with a 79.6% complete response rate at three months. UroGen completed its NDA submission to the FDA with a PDUFA date of June 13, 2025. The treatment demonstrated mild-to-moderate side effects, consistent with previous trials.

UroGen Pharma ha annunciato risultati promettenti dallo studio di Fase 3 ENVISION su UGN-102 per il trattamento del carcinoma della vescica non muscolo-invasivo a rischio intermedio di basso grado (LG-IR-NMIBC). Lo studio ha mostrato una durata della risposta dell'82,3% a 12 mesi nei pazienti che hanno ottenuto una risposta completa. Il trial ha raggiunto l'endpoint primario con un tasso di risposta completa del 79,6% a tre mesi. UroGen ha completato la sua domanda NDA presso la FDA con una data PDUFA fissata per il 13 giugno 2025. Il trattamento ha dimostrato effetti collaterali da lievi a moderati, in linea con prove precedenti.

UroGen Pharma anunció resultados prometedores del estudio de Fase 3 ENVISION de UGN-102 para el tratamiento del cáncer de vejiga no músculo-invasivo de riesgo intermedio de bajo grado (LG-IR-NMIBC). El estudio mostró una duración de respuesta del 82,3% a 12 meses en pacientes que lograron una respuesta completa. El ensayo cumplió con su objetivo principal con una tasa de respuesta completa del 79,6% a los tres meses. UroGen completó su presentación de NDA a la FDA con una fecha PDUFA del 13 de junio de 2025. El tratamiento demostró efectos secundarios leves a moderados, consistentes con ensayos previos.

UroGen Pharma는 저급 중간 위험 비근육 침습성 방광암(LG-IR-NMIBC) 치료를 위한 UGN-102의 3상 ENVISION 연구에서 유망한 결과를 발표했습니다. 이 연구는 완전 반응을 보인 환자에서 12개월 동안 82.3%의 반응 지속 기간을 나타냈습니다. 이 시험은 3개월 차에 79.6%의 완전 반응률로 주요 목표를 달성했습니다. UroGen은 FDA에 NDA 제출을 완료했으며 PDUFA 날짜는 2025년 6월 13일입니다. 치료는 이전 시험과 일치하는 경미한-중간 정도의 부작용을 나타냈습니다.

UroGen Pharma a annoncé des résultats prometteurs de l'étude de phase 3 ENVISION sur UGN-102 pour le traitement du cancer de la vessie non invasif à faible grade de risque intermédiaire (LG-IR-NMIBC). L'étude a montré une durée de réponse de 82,3% à 12 mois chez les patients ayant obtenu une réponse complète. L'essai a atteint son critère principal avec un taux de réponse complet de 79,6% à trois mois. UroGen a complété sa soumission de NDA auprès de la FDA avec une date PDUFA prévue pour le 13 juin 2025. Le traitement a démontré des effets secondaires légers à modérés, cohérents avec les essais précédents.

UroGen Pharma gab vielversprechende Ergebnisse aus der Phase-3-Studie ENVISION zu UGN-102 bekannt, die zur Behandlung von niedriggradigem intermediärem Risiko bei nicht muskelinvasivem Blasenkrebs (LG-IR-NMIBC) eingesetzt wird. Die Studie zeigte eine Reaktionsdauer von 82,3% über 12 Monate bei Patienten mit kompletter Ansprechrate. Der Test erreichte sein Hauptziel mit einer kompletten Ansprechrate von 79,6% nach drei Monaten. UroGen hat die NDA-Einreichung bei der FDA abgeschlossen, und das PDUFA-Datum ist der 13. Juni 2025. Die Behandlung wies milde bis moderate Nebenwirkungen auf, die mit früheren Studien übereinstimmen.

Positive
  • High efficacy with 82.3% duration of response at 12 months
  • Strong complete response rate of 79.6% at three months
  • NDA submission completed ahead of schedule
  • Potential to be first FDA-approved non-surgical treatment for LG-IR-NMIBC
  • Favorable safety profile with mild-to-moderate side effects
Negative
  • PDUFA decision not expected until June 2025
  • Treatment associated with various side effects including dysuria and hematuria

Insights

The Phase 3 ENVISION trial results for UGN-102 represent a significant breakthrough in bladder cancer treatment. The 82.3% duration of response at 12 months and 79.6% complete response rate at three months are remarkably high for non-surgical intervention. The data is particularly compelling given the current standard of care involves repeated surgeries under general anesthesia.

The trial's robust sample size and extended follow-up period (up to 18 months) provide strong statistical validity. The consistent durability of response, maintaining 80.9% at both 15 and 18 months, suggests long-term efficacy. The safety profile, showing primarily mild-to-moderate manageable side effects, positions UGN-102 favorably for FDA approval.

With the NDA submission completed and a PDUFA date set for June 13, 2025, UGN-102 could become the first FDA-approved non-surgical treatment for LG-IR-NMIBC, potentially transforming the treatment landscape for elderly patients who are particularly vulnerable to surgical complications.

  • The Kaplan-Meier Estimate of Duration of Response at 12 Months in Patients Who Achieved a Complete Response at Three Months was 82.3%
  • Patients Receiving UGN-102 had a 79.6% Complete Response Rate at Three Months
  • Side Effect Profile Consistent with Previous Clinical Trials of UGN-102

PRINCETON, N.J,--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that new long-term durability of response results from the Phase 3 ENVISION study of investigational drug UGN-102 in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) were published online in the Journal of Urology.

In ENVISION, UGN-102 treatment was associated with an unprecedented 82.3% (95% CI, 75.9%, 87.1%) 12-month duration of response (DOR) by Kaplan-Meier estimate (n=108) in patients who achieved complete response (CR) at three months after the first instillation of investigational drug UGN-102 (mitomycin) for intravesical solution. The DOR Kaplan-Meier estimates at 15 months (n=43) and 18 months (n=9) after 3-month CR were both 80.9% (95% CI, 73.9%, 86.2%). The ENVISION trial previously met its primary endpoint by demonstrating that patients treated with UGN-102 had a 79.6% (95% CI, 73.9%, 84.5%) CR rate at three months following the first instillation of UGN-102.

“These data demonstrate that treatment with UGN-102 results in a clinically meaningful CR rate and that the durability of the response in patients with LG-IR-NMIBC is robust,” said Sandip Prasad, MD, M.Phil., Director of Genitourinary Surgical Oncology, Morristown Medical Center/Atlantic Health System, NJ and Principal Investigator of the ENVISION trial. “This study adds to the mounting evidence supporting UGN-102 as a potentially valuable treatment option for patients with recurrent LG-IR-NMIBC.”

UroGen initiated the submission of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for UGN-102 as a treatment for LG-IR-NMIBC in January 2024 and completed the NDA submission in August, ahead of schedule. The FDA accepted the NDA for UGN-102 with a PDUFA goal date of June 13, 2025.

Liz Barrett, President and CEO of UroGen, emphasized the significance of the DOR findings from the ENVISION study, stating, “LG-IR-NMIBC patients are typically elderly and currently treated with repeated surgeries under general anesthesia that are associated with physical and quality of life detriments. These new results continue to strengthen UGN-102’s potential as a treatment option for these patients that extends their recurrence-free interval. The highly recurrent nature of LG-IR-NMIBC underscores the urgent need for innovative options for patients facing this challenging disease."

The most common treatment-emergent adverse events (TEAEs) in the ENVISION trial were dysuria, hematuria, urinary tract infection, pollakiuria, fatigue, and urinary retention. TEAEs were typically mild-to-moderate in severity and resolved or resolving. The ENVISION trial demonstrated a similar safety profile to that observed in other studies of UGN-102.

About UGN-102

UGN-102 (mitomycin) for intravesical solution is an innovative drug formulation of mitomycin, currently in Phase 3 development for the treatment of LG-IR-NMIBC. Utilizing UroGen’s proprietary RTGel® technology, a sustained release, hydrogel-based formulation, UGN-102 is designed to enable longer exposure of bladder tissue to mitomycin, thereby enabling the treatment of tumors by non-surgical means. UGN-102 is delivered to patients using a standard urinary catheter in an outpatient setting by a trained healthcare professional. UroGen completed the NDA submission in August, ahead of schedule. The FDA accepted the NDA for UGN-102 and assigned a PDUFA goal date of June 13, 2025.

About Non-Muscle Invasive Bladder Cancer (NMIBC)

In the U.S., bladder cancer is the second most common urologic cancer in men. LG-IR- NMIBC represents approximately 22,000 newly diagnosed bladder cancer patients each year and an estimated 60,000 recurrences annually among patients diagnosed from previous years. Bladder cancer primarily affects older populations with increased risk of comorbidities, with the median age of diagnosis being 73 years. Guideline recommendations for the management of NMIBC include trans-urethral resection of bladder tumor (TURBT) as the standard of care. Up to 70 percent of NMIBC patients experience at least one recurrence and LG-IR-NMIBC patients are even more likely to recur and face repeated TURBT procedures.

About ENVISION

The Phase 3 ENVISION trial is a single-arm, multinational, multicenter study evaluating the efficacy and safety of UGN-102 (mitomycin) for intravesical solution as a chemoablative therapy in patients with LG-IR-NMIBC. The Phase 3 ENVISION trial completed target enrollment with approximately 240 patients across 56 sites. Study participants received six once-weekly intravesical instillations of UGN-102. The primary endpoint evaluated the CR rate at the three-month assessment after the first instillation, and the key secondary endpoint evaluated durability over time in patients who achieved a CR at the three-month assessment. Learn more about the Phase 3 ENVISION trial at www.clinicaltrials.gov (NCT05243550).

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with LG-IR-NMIBC are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X (Twitter), @UroGenPharma.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the potential for UGN-102 as the first FDA-approved chemoablative, non-surgical treatment for LG-IR-NMIBC; the estimated annual U.S. patient population and demographics for LG-IR-NMIBC; the potential benefits to patients and opportunities for UGN-102, if approved; statements related to UroGen’s NDA submission for UGN-102 and the potential approval and timing thereof; the potential of UroGen’s proprietary RTGel technology to improve therapeutic profiles of existing drugs; and UroGen’s sustained release technology making local delivery potentially more effective as compared to other treatment options. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: even though the NDA for UGN-102 has been accepted for filing by the FDA, there is no guarantee that such NDA will be sufficient to support approval of UGN-102 on the timeframe expected, or at all; the ability to maintain regulatory approval; complications associated with commercialization activities; the labeling for any approved product; competition in UroGen’s industry; the scope, progress and expansion of developing and commercializing UroGen’s product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies; UroGen’s ability to attract or retain key management, members of the board of directors and other personnel; UroGen’s RTGel technology may not perform as expected; and UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 13, 2024 (which is available at www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.

INVESTOR CONTACT:

Vincent Perrone

Senior Director, Investor Relations

vincent.perrone@urogen.com

609-460-3588 ext. 1093

MEDIA CONTACT:

Cindy Romano

Director, Communications

cindy.romano@urogen.com

908-963-7827

Source: UroGen Pharma Ltd.

FAQ

What was the duration of response rate for UGN-102 (URGN) in the ENVISION trial?

The ENVISION trial showed an 82.3% duration of response rate at 12 months for patients who achieved complete response at three months after UGN-102 treatment.

When is the PDUFA date for UroGen's (URGN) UGN-102?

The FDA set a PDUFA goal date of June 13, 2025, for UGN-102's New Drug Application.

What was the complete response rate in the ENVISION trial for UGN-102 (URGN)?

The ENVISION trial demonstrated a 79.6% complete response rate at three months following the first instillation of UGN-102.

What are the main side effects of UGN-102 (URGN) reported in the ENVISION trial?

The most common side effects included dysuria, hematuria, urinary tract infection, pollakiuria, fatigue, and urinary retention, typically mild-to-moderate in severity.

UroGen Pharma Ltd. Ordinary Shares

NASDAQ:URGN

URGN Rankings

URGN Latest News

URGN Stock Data

510.00M
42.11M
9.2%
93.72%
15.41%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
RA'ANANA